GITNUX MARKETDATA REPORT 2024
Pregabalin Onset Efficacy For Nerve Pain Statistics
Pregabalin has demonstrated significant onset efficacy for nerve pain based on statistical analysis of relevant clinical trials.
In this post, we explore the efficacy of Pregabalin in managing nerve pain, backed by a comprehensive analysis of key statistics from clinical trials. From the rapid onset of pain relief to improvements in sleep disturbances, we delve into the tangible benefits experienced by patients undergoing Pregabalin treatment.
Statistic 1
"Pregabalin is effective in reducing neuropathic pain within the first week of treatment in 48% of patients."
Statistic 2
"Pregabalin can improve sleep disturbances in 63% of patients with nerve pain within the first week of treatment."
Statistic 3
"In clinical trials, the median time to onset of significant pain relief for Pregabalin was 4 days for nerve pain."
Statistic 4
"On average, patients treated with Pregabalin experienced a mean reduction of nerve pain score by 2.49."
Statistic 5
"A total of 35% of patients report a reduction in nerve pain with Pregabalin after one week of treatment."
Statistic 6
"The efficacy of Pregabalin for managing diabetic peripheral neuropathic pain is 50%."
Statistic 7
"By 12 weeks, nearly 60% of patients experience a significant reduction in nerve pain with Pregabalin."
Statistic 8
"Pregabalin reduced weekly mean pain scores by at least 50% in 45% of patients with neuropathic pain."
Statistic 9
"After 4-6 weeks of treatment, pregabalin reduced the pain intensity by approximately 2.2 points on a 10-point scale."
Statistic 10
"Pregabalin has been found to reduce sleep interference score by an average of 2.63 in patients with neuropathic pain."
Statistic 11
"The duration of exposure ranged from 1 day to 1462 days with an average duration of exposure of 274 days in clinical trials."
Statistic 12
"Pregabalin was associated with a greater number of adverse events than alternative adjunctive drugs (26% vs 14%)."
Statistic 13
"An estimated 246.2 patients per 1000 would benefit from pregabalin compared with 175 per 1000 treated with placebo."
